New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2013
13:43 EDTSRPT, GSKDuchenne muscular dystrophy patients hospitalized, TheStreet says
Duchenne muscular dystrophy patients treated with drisapersen, GlaxoSmithKline's (GSK) experimental drug, have been hospitalized, according to a report by TheStreet that cites a Glaxo scientist speaking in Rome last Sunday. The report notes that Sarepta Therapeutics (SRPT) is meeting with the FDA this quarter to discuss the possibility of an accelerated approval filing for its Duchenne muscular dystrophy drug eteplirsen. Reference Link
News For GSK;SRPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 6, 2015
10:24 EDTSRPTOptions with increasing implied volatility
Options with increasing implied volatility: UVXY MBI AMBC VIX FIT SRPT VXX GREK SVXY GNW
July 2, 2015
18:37 EDTGSKViiV, Desano enter strategic manufacturing agreement for Tivicay
Subscribe for More Information
10:48 EDTSRPTOptions with increasing implied volatility
Subscribe for More Information
June 30, 2015
10:26 EDTSRPTOptions with increasing implied volatility
Subscribe for More Information
June 29, 2015
12:53 EDTSRPTSarepta NDA submission for eteplirsen done ahead of schedule, says Piper Jaffray
Piper Jaffray noted that Sarepta (SRPT) completed its rolling NDA submission for eteplirsen ahead of schedule and the firm believes that concurrent advisory committee meetings for its DMD drug and BioMarin's (BMRN) drisapersen could take place this fall. The firm has a Neutral rating and $20 price target on Sarepta and Overweight rating and $147 target on BioMarin.
07:05 EDTSRPTSarepta completes NDA submission to FDA for eteplirsen
Subscribe for More Information
07:03 EDTSRPTSarepta secures $40M in debt financing
Sarepta Therapeutics announced that it entered into a credit and security agreement with Midcap Financial, a middle market-focused, specialty finance firm, that establishes a senior secured term loan facility that allows Sarepta to borrow up to $40M at an annual rate of 7.75%, with a maturity of June 2018, subject to certain conditions and other applicable fees. Sarepta has drawn down $20M under the facility and has the right to repay all borrowed funds and terminate the facility at any time.
June 26, 2015
11:00 EDTSRPTOptions with increasing implied volatility
Options with increasing implied volatility: SRPT AGO CRC WMB AMZN CMG TRIP ZTS AET MBI
10:38 EDTGSKCourt revives lawsuit over GlaxoSmithKline Lamictal drug, Bloomberg reports
Subscribe for More Information
June 25, 2015
14:01 EDTGSKGlaxoSmithKline initiated with a Buy at HSBC
Price target GBP 17.
12:59 EDTSRPTOptions with increasing implied volatility
Subscribe for More Information
June 24, 2015
13:37 EDTGSKGSK says CDC committee votedfor meningococcal group B vaccines
GlaxoSmithKline (GSK) announced that the U.S. Centers for Disease Control Advisory Committee on Immunization Practices voted for a Category B recommendation for meningococcal group B vaccination, including Bexsero, in individuals aged 16 to 23. Bexsero was approved by the FDA in January for use in individuals aged 10 through 25 years and acquired by GSK in March following the closure of the three-part transaction with Novartis (NVS).
June 23, 2015
07:25 EDTGSKPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use